After seeing a 100 percent response rate in Phase I, Indian health authorities said the firm can test ribrecabtagene autoleucel in Phase II of the SWASTH trial.

The London-based firm said it will use the funds to advance its gene therapy pipeline, including its lead program in IgA nephropathy.

The firm is focusing its resources on developing its lead candidate, the EGFR inhibitor BDTX-1535, which is undergoing testing in EGFR-mutated NSCLC.

The new consortium, dubbed Thera4Care, launched with €25.3 million in EU government funding and 29 academic and industry partners.

The partners are studying a drug designed to target EGFR exon 19 or exon 21 mutations with a co-occurring C797S mutation.

In the HAELO trial, the firm will randomize 60 HAE patients to NTLA-2002 or placebo and compare the number of inflammatory attacks.

Astellas will make a $20 million equity investment in AviadoBio for the option to exclusively develop and commercialize AVB-1010.

The Francis Crick Institute and the Royal Marsden Foundation Trust are spearheading the MANIFEST project with £21.9 million in government and industry funding.

After the latest funding and merger, OnKure will have enough resources to support operations into Q4 2026, including development of its PI3Kα inhibitors.

CSPC will also be eligible for up to nearly $2 billion in development and commercialization milestones tied to the lipoprotein(a) disruptor.

The trial will include patients with newly diagnosed, treatment-naïve cancers as well as those with recurrent or metastatic disease.

Researchers explored whether the uptake of pre-test education and cancer risk genetic testing was similar for patients who ...